Targeting Ischemic Disease with DiaMedica CEO Rick Pauls — Episode 254

In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke Rick Pauls, President and CEO of DiaMedica Therapeutics (Nasdaq: DMAC), a company advancing multiple programs in challenging vascular conditions driven by ischemia, including preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS).

DiaMedica’s therapeutic approach in ischemia-based diseases centers on a recombinant form of the KLK1 protein, which plays a key role in regulating blood flow, reducing inflammation and supporting vascular health.

Rick Pauls has served as President and CEO of DiaMedica since 2009 and has been a board member since 2005, including as Chair from 2008 to 2014. Previously, he co-founded and led CentreStone Ventures, an early-stage life sciences venture capital fund, worked as an analyst at Centara Corporation and specialized in asset-backed securitization and structured finance at General Motors Acceptance Corporation. He has also served on the boards of several public and private companies. Rick received his BA in Economics from the University of Manitoba and his MBA in Finance from the University of North Dakota.

Tune in to hear about a novel therapeutic approach to treating ischemia-driven diseases like stroke and preeclampsia.

The weekly podcast is available for streaming every Wednesday on Spotify, Apple Music and wherever you stream your podcasts.

Subscribe to the Xtalks Life Science Podcast to never miss a new episode.